Disc Medicine (IRON) to Release Quarterly Earnings on Thursday

Key Points

• Disc Medicine (NASDAQ:IRON) is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($1.17) per share.
• The company's stock recently opened at $59.00 and has seen a 52-week low of $30.82 and a high of $68.73, currently holding a market cap of $2.04 billion.
• Insider trading activity includes CEO John D. Quisel selling 34,800 shares at an average price of $55.33, resulting in a significant decrease of 17.70% in his ownership stake.

Disc Medicine (NASDAQ:IRON - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect Disc Medicine to post earnings of ($1.17) per share for the quarter.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.41). On average, analysts expect Disc Medicine to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Disc Medicine Trading Up 1.7%

IRON traded up $0.96 during trading on Friday, reaching $58.03. The company had a trading volume of 274,640 shares, compared to its average volume of 405,642. The company has a quick ratio of 37.65, a current ratio of 37.65 and a debt-to-equity ratio of 0.04. The business has a 50 day simple moving average of $54.78 and a 200-day simple moving average of $51.46. The stock has a market cap of $2.01 billion, a P/E ratio of -14.80 and a beta of 0.77. Disc Medicine has a 52 week low of $30.82 and a 52 week high of $68.73.

Insider Transactions at Disc Medicine

In related news, Director Kevin Bitterman sold 29,837 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $60.97, for a total value of $1,819,161.89. Following the completion of the sale, the director directly owned 647,002 shares of the company's stock, valued at $39,447,711.94. This represents a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John D. Quisel sold 34,800 shares of the business's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $55.33, for a total transaction of $1,925,484.00. Following the completion of the sale, the chief executive officer owned 161,828 shares of the company's stock, valued at approximately $8,953,943.24. This represents a 17.70% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 108,125 shares of company stock worth $6,234,626. Corporate insiders own 4.24% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in IRON. Millennium Management LLC increased its holdings in shares of Disc Medicine by 1,277.1% in the first quarter. Millennium Management LLC now owns 108,499 shares of the company's stock valued at $5,386,000 after purchasing an additional 100,620 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Disc Medicine by 3.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company's stock valued at $4,793,000 after buying an additional 3,454 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Disc Medicine by 22.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company's stock valued at $756,000 after buying an additional 2,807 shares during the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IRON has been the subject of several analyst reports. Truist Financial initiated coverage on shares of Disc Medicine in a report on Monday, July 21st. They issued a "buy" rating and a $86.00 target price for the company. Raymond James Financial began coverage on Disc Medicine in a research report on Wednesday, June 11th. They set a "strong-buy" rating and a $89.00 target price for the company. BMO Capital Markets upped their target price on Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research note on Monday, May 12th. Wedbush reissued an "outperform" rating and set a $90.00 price target on shares of Disc Medicine in a research note on Monday, July 21st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $118.00 price objective on shares of Disc Medicine in a research report on Thursday, July 3rd. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $95.73.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.